Skip to main content
delveinsight blog
  • ABOUT
    • About Us
    • Our Leadership
    • Our Clients
  • CAPABILITIES & SOLUTIONS
    • Reports
    • Competitive Intelligence
    • Case Study
  • CONSULTING SERVICE
  • REPORT STORE
  • MEDIA
    • Blog
    • Press Releases
    • White Papers / Newsletter
    • Events
  • CAREER
  • CONTACT US
  • Report Store

Month: September 2017

Sep 28 NOTIZIA

NOTIZIA

Sep 28, 2017 DelveInsight Leave a comment

Another flop for Alzeimer’s as Late Stage drug of AxovantSciences fails in trial Axovant Sciences has reported the failure of their late-stage trial involving the testing of…

Read More
Sep 25 Anaplastic Astrocytoma: The rare disease with huge unmet medical need

Anaplastic Astrocytoma: The rare disease with huge unmet medical need

Sep 25, 2017 DelveInsight Leave a comment

Anaplastic Astrocytoma (AA) is a rare type of malignant brain tumor. As per World Health Organization (WHO) grading system, AA is classified Grade III astrocytomas.  Grade…

Read More
Sep 22 Isocitrate dehydrogenase (IDH) inhibitors– Emerging Anti-Cancer Therapeutics

Isocitrate dehydrogenase (IDH) inhibitors– Emerging Anti-Cancer Therapeutics

Sep 22, 2017Sep 22, 2017 DelveInsight Leave a comment

The enzyme, isocitrate dehydrogenase (IDH) catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate and CO2. It is found in the cytosol, mitochondrial matrix, and peroxisomes. IDH…

Read More
Sep 20 Business Cocktail

Business Cocktail

Sep 20, 2017Sep 20, 2017 DelveInsight Leave a comment

Chinese pharma company Shanghai Fosun to acquire 74% stake in Indian company Gland Pharma for $1.09 billion In July last year Chinese company Shanghai Fosun Pharmaceutical…

Read More
Sep 19 Notizia

Notizia

Sep 19, 2017 DelveInsight Leave a comment

Thrombolytic Sciences announced completion of Phase I TS01 trial A clinical stage vascular health and biotech company, Thrombolytic Science, LLC (TSI), announced the completion of its…

Read More
Sep 18 Oral Mucositis – A Common Cancer Therapy Adverse Reaction

Oral Mucositis – A Common Cancer Therapy Adverse Reaction

Sep 18, 2017Sep 18, 2017 DelveInsight Leave a comment

Oral Mucositis is a commonly occurring, most debilitating complication of cancer chemotherapy and radiotherapy. It can be characterized by inflammation and ulceration in the oral cavity…

Read More
Sep 15 Human Papillomavirus (HPV) Prophylaxis– Expected to see a steady growth from 2015-2025

Human Papillomavirus (HPV) Prophylaxis– Expected to see a steady growth from 2015-2025

Sep 15, 2017Sep 15, 2017 DelveInsight Leave a comment

A total of approximately 7.3 Million people were vaccinated with HPV vaccines in 2016, as per the latest report of DelveInsight. Human Papillomavirus is a double…

Read More
Sep 15 Business cocktail

Business cocktail

Sep 15, 2017 DelveInsight Leave a comment

Bayer and Berkeley Lights embark on a project to automate drug discovery Pharmaceutical giant Bayer and Berkeley Lights have announced their collaboration to conduct a strategic…

Read More
Sep 13 The Snippet: South Korean researchers Lobbying to influence lift of human-embryo restrictions

The Snippet: South Korean researchers Lobbying to influence lift of human-embryo restrictions

Sep 13, 2017 DelveInsight Leave a comment

It has been more than 10 years that a scandal related to stem cell research rocked South Korea, leading to a ban on human embryo research,…

Read More
Sep 12 Notizia

Notizia

Sep 12, 2017 DelveInsight Leave a comment

Idera Pharmaceuticals Present Positive Phase I Data for their Drug candidate IMO-2125 Idera Pharmaceuticals announced final results from the dose-selection phase of an ongoing Phase 1/2…

Read More

Posts navigation

1 2 Older posts

Recent Posts

  • Human cells reprogrammed to create insulin in diabetic mice
  • The Business cocktail
  • The antidepressant drug gets support from FDA
  • Notizia
  • Raynaud’s Disease -A debilitating condition

Browse by Category

  • Anti-coagulants (6)
  • API Business Opportunity (3)
  • Articles (182)
  • Atrial Fibrillation (3)
  • Business Consultant (224)
    • Pharma Consultant (208)
  • Chimeric Antigen Receptor (CAR) T-cell Therapy (3)
  • CNS Indications (1)
  • CVS Indications (4)
  • DelveInsight's Drug Report (22)
  • DelveInsight's Indication Pipeline Reports (8)
  • DelveInsight's Oncology based Reports (14)
  • Gene Therapy Products (29)
  • Infographics (11)
  • new therapeutic target (2)
  • Newsletter (2)
  • Notizia (98)
  • Oncology based Indications (7)
  • Orphan market (3)
  • PD-1 and PD-L1 inhibitors (5)
  • Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors (1)
  • Pulmonary arterial hypertension (1)
  • Rising of Orphan Drug Development (2)
  • Snippets (96)
  • Specialized Reports (15)
  • The Business Cocktail (85)
  • Uncategorized (61)
  • Venous Thromboembolism (3)

Archives

  • February 2019 (11)
  • January 2019 (18)
  • December 2018 (19)
  • November 2018 (26)
  • October 2018 (21)
  • September 2018 (20)
  • August 2018 (26)
  • July 2018 (13)
  • June 2018 (5)
  • May 2018 (8)
  • April 2018 (6)
  • March 2018 (14)
  • February 2018 (11)
  • January 2018 (15)
  • December 2017 (8)
  • November 2017 (13)
  • October 2017 (8)
  • September 2017 (14)
  • August 2017 (13)
  • July 2017 (9)
  • June 2017 (14)
  • May 2017 (20)
  • April 2017 (19)
  • March 2017 (24)
  • February 2017 (21)
  • January 2017 (23)
  • December 2016 (22)
  • November 2016 (23)
  • October 2016 (17)
  • September 2016 (21)
  • August 2016 (17)
  • May 2016 (4)
  • March 2016 (8)
  • February 2016 (3)
  • January 2016 (7)
  • November 2015 (1)
  • October 2015 (1)
  • September 2015 (2)
  • August 2015 (2)
  • July 2015 (8)
  • June 2015 (4)
  • May 2015 (1)
  • April 2015 (5)
  • March 2015 (6)
  • February 2015 (2)
  • January 2015 (5)
  • December 2014 (17)
  • November 2014 (2)
  • September 2014 (1)
  • August 2014 (7)
  • July 2014 (7)
delveinsight


Quick Links

  • About
  • Capabilities & Solutions
  • Report Store
  • Media
  • Career
  • Contact Us

Contact Us

Phone

India: +91-11-45689769, +91-9650213330

Email

info@delveinsight.com

Address

New Delhi-110075, India

Address

304 S. Jones Blvd #2432, Las Vegas NV 89107

Phone

Outside India: +1(919)321-6187

Latest Tweets

Tweets by @DelveInsight

Copyright © 2019 Delveinsight.

  • Sitemap
  • Terms & Conditions
  • Privacy policy